All articles tagged with #cerebral folate deficiency
FDA officials say there’s insufficient data to approve leucovorin for autism, reversing earlier optimism from RFK Jr. and FDA Commissioner Makary; the drug is now approved for a rare CFD-FOLR1–related cerebral folate deficiency, with off-label autism use left to physician discussion and future research; the initial trial cited in support of autism benefits was retracted, underscoring data limitations.
The FDA approved leucovorin for cerebral folate deficiency and clarified it is not approved to treat autism; data on autism efficacy is insufficient, though doctors may prescribe it off-label, and prescriptions rose after earlier statements from officials.
The FDA approved leucovorin (folinic acid) as the first treatment for cerebral folate deficiency—a rare genetic disorder that prevents folate from reaching the brain—in select adults and children. The decision was based on a systematic review of published case data rather than a randomized trial and did not establish broad efficacy for autism, though future autism studies remain possible. The approval covers generic leucovorin and GSK’s Wellcovorin, and regulators urged manufacturers to boost production to meet rising demand; GSK has no plans to relaunch the product.
Families have been using leucovorin, a drug originally for cancer, to treat autism symptoms, gaining attention after President Trump mentioned it. While some studies suggest potential benefits, the evidence is limited and the FDA's recent move to update the drug's label is considered unusual and controversial due to weak supporting data. Experts emphasize the need for more research and caution in its use.
Leucovorin, a drug approved for chemotherapy side effects, is being explored as a potential treatment for autism related to cerebral folate deficiency. While some small studies and anecdotal reports suggest improvements in communication and behavior, there is not enough rigorous scientific evidence to confirm its safety and efficacy for autism, raising concerns about premature approval and unregulated use. The FDA plans to update its labeling to reflect potential benefits, but experts warn against overestimating the current evidence.
The FDA approved leucovorin, a form of folic acid, which was suggested by President Trump as a potential treatment for autism symptoms, based on data indicating it may improve symptoms related to cerebral folate deficiency, a condition associated with neuropsychiatric symptoms including autistic features.